Exploring New Horizons: Clinical Trials Advancing Targeted and Personalized

Facing a diagnosis of urothelial cancer can feel overwhelming, but it’s important to remember that you are not alone, and there are new reasons to remain hopeful. Every day, advancements in cancer research bring more personalized and targeted options. Cutting-edge clinical trials are now available, designed to explore innovative options that aim to improve patient outcomes and quality of life. By participating in a clinical trial, you not only gain access to the latest options but also take an active role in the fight against this disease. Your path to better health could begin with one of these promising studies.

Compliance and Security Certifications

[EN] Ads Landing Pages - United States & Canada - English
Let's Explore Your Options
By filling out this form, you're consenting only to release your medical records. You're not agreeing to participate in clinical trials yet.

Massive Bio has onboarded over 160,000 cancer patients to find their clinical trial

Our matching system connects you with the most up-to-date clinical trials, opening new possibilities for those living with urothelial carcinoma. Through the Massive Bio platform, you can access detailed information about clinical trials for every stage of the disease. These trials include new options and combinations specifically designed to target urothelial carcinoma. By participating, you can actively fight the disease alongside our team.

By analyzing your medical records and utilizing our advanced AI system, we identify clinical trials that may be a good fit for you. We also provide a personalized concierge service to ensure a smooth transition into these trials. Our dedicated team of nurses and doctors will guide you through every step, from beginning to end. These services are completely free for both you and your oncologist.

The most common type of cancer in the urothelial regions is urothelial carcinoma, also known as transitional cell carcinoma (TCC). It is the most common form of cancer in the lower urinary tract, affecting the bladder and urethra. It can also arise in the upper urinary tract, including the kidneys and ureters, though it is less common in these areas. This cancer starts in the urothelium, a special type of tissue that lines much of the urinary tract and serves as a barrier to hold urine while preventing toxins from re-entering the body. Urothelial cancers are often linked to genetic mutations, such as changes in the p53 gene, which can cause the urothelial cells to grow uncontrollably and invade nearby tissues. Risk factors like smoking, alcohol use, and chemical exposure also increase the likelihood of developing urothelial carcinoma.

Urothelial cancer includes cancers that originate in the urothelial cells, which line much of the urinary tract. These cells are found in several parts of the body, leading to different types of urothelial cancer. The main areas affected by urothelial cancer include:

Bladder Urothelial Carcinoma: The most common type, originating in the bladder’s inner lining. It can be classified into two categories:

  • Non-muscle-invasive: Cancer confined to the bladder lining or just beneath it.
  • Muscle-invasive: Cancer that has spread into the bladder’s muscular wall.
  • Urethral Urothelial Carcinoma: This cancer develops in the urethra, the tube that carries urine from the bladder out of the body.
  • Upper Tract Urothelial Carcinoma: Occurring in the renal pelvis (the part of the kidney that collects urine before it moves to the ureter) or ureters (the tubes that carry urine from the kidneys to the bladder), these cancers are less common than bladder cancer.

Common Symptoms of Urothelial Cancer

  • Hematuria: Blood in the urine, causing it to appear pink, red, or brown.
  • Dysuria: Painful or burning sensations while urinating.
  • Pelvic or Lower Back Pain: Can develop as the cancer progresses and presses on nearby organs or nerves.
  • Urinary Urgency: A sudden, strong need to urinate, even when the bladder is not full.
  • Urinary Incontinence: Difficulty controlling urine flow.

Recognizing these symptoms early can make a crucial difference in your treatment options and outcomes. Don’t ignore symptoms like blood in your urine or pain during urination, as early detection often leads to more effective treatment.

Understanding the stage of urothelial carcinoma is vital for determining how far the cancer has spread and what treatments are most appropriate. The stage helps doctors decide whether the tumor is limited to the bladder lining or has grown deeper into the muscle or other tissues. This information allows patients to feel informed and confident in their treatment choices.

1. Lower urinary tract urothelial carcinomas: This includes urothelial carcinomas that originate in the bladder and urethra. The stages are divided as follows:

  • Stage 0: The tumor affects only the inner lining of the bladder or urethra, without invading deeper layers.
  • Stage 1: An early stage where the cancer has invaded the lamina propria (a thin layer beneath the bladder or urethral lining) but has not yet reached the muscle layer.
  • Stage 2: A localized stage where the tumor has grown into the muscle layer, either the inner (superficial) or outer (deep) muscle.
  • Stage 3: A locally advanced stage where the tumor has spread into the surrounding fatty tissue or nearby organs (e.g., prostate, uterus, or vagina) or has spread to a single regional lymph node.
  • Stage 4: An advanced or metastatic stage where the tumor has spread to adjacent organs, multiple lymph nodes, or metastasized to distant organs.

2. Upper urinary tract urothelial carcinomas: This includes carcinomas that originate in the ureters or renal pelvis. The stages are divided as follows:

  • Stage 0: The cancer is limited to the inner lining of the ureter or renal pelvis and has not invaded deeper tissues.
  • Stage 1: An early stage where the cancer has grown from the inner lining into the layer just beneath it (lamina propria) but has not yet reached the muscle.
  • Stage 2: A localized stage where the tumor has spread into the muscle layer of the ureter or renal pelvis.
  • Stage 3: A locally advanced stage where the tumor has invaded the fat surrounding the ureter or renal pelvis.
  • Stage 4: An advanced stage where the cancer has spread to nearby lymph nodes, deeply invaded nearby organs (e.g., bladder, bowel, or abdominal wall), or metastasized to distant organs.

Treated Urothelial Carcinoma: Cancer that has undergone treatment, such as surgery, chemotherapy, immunotherapy, or radiation. Regular follow-ups are essential to monitor for recurrence.

Untreated Urothelial Carcinoma: Cancer that has been diagnosed but not yet treated. Clinical trials offer new treatment possibilities for both treated and untreated cases, providing access to cutting-edge therapies.

Resectable: Cancer that can be surgically removed. Tumors that have not spread too far can often be treated with surgery, offering a better chance of cure.

Unresectable: Cancer that cannot be completely removed by surgery due to its location or spread. Other treatments like chemotherapy, radiation, or targeted therapies are typically used in these cases.

Understanding whether your cancer is resectable or not is essential in choosing the best path and can open up options for advanced options in clinical trials.

Surgery:

The type of surgery you receive will mainly depend on the stage of your cancer, with emphasis on the size of the tumor.

  • I.Nephroureterectomy: This surgery is usually recommended for more advanced cancers or when the tumor has invaded deeper tissues. It is the most common treatment for urothelial carcinoma in the renal pelvis or ureter. The procedure involves removing the kidney, the affected ureter, and part of the bladder.
  • II.Segmental Ureterectomy: Recommended for smaller tumors confined to the ureter. It involves removing only the affected portion of the ureter.
  • III.Endoscopic Surgery: Minimally invasive procedures can be used for smaller, non-invasive tumors.

Intravesical Therapy: This treatment is typically recommended for early-stage cancers. It involves delivering medications (such as BCG or chemotherapy) directly into the renal pelvis to help prevent the cancer from returning or progressing.

Systemic Chemotherapy: Used for more advanced urothelial carcinoma that has spread beyond the kidney or ureter. This treatment involves administering anti-cancer drugs that circulate throughout the body to target cancer cells. It can also be used before or after surgery to reduce the risk of recurrence or to manage cancer that cannot be completely removed surgically.

Immunotherapy: This treatment helps the body’s immune system recognize and attack cancer cells. It is typically used for advanced, recurrent, or metastatic cancers, especially when other treatments have not been effective.

  • Anti-PDL1: These drugs block proteins that prevent immune cells from attacking tumors, thereby enhancing the immune response.

Radiation Therapy: In some cases, radiation can be used to treat urothelial carcinoma in the renal pelvis or ureter, particularly when surgery is not an option or to relieve symptoms in advanced cases.

Targeted Therapy: This type of treatment uses drugs designed to specifically target and block molecules or proteins that are essential for cancer cell growth and survival. Unlike traditional chemotherapy, targeted therapy focuses on attacking cancer cells while minimizing damage to healthy cells.

  • FGFR Inhibitors: These drugs block the abnormal activity of FGFR proteins, preventing cancer cells from multiplying and helping to shrink the tumor.
  • mTOR Inhibitors: These drugs block the activity of the mTOR protein, stopping the signals that encourage cancer cell growth and spread.
  • ERBB2 (HER2) Inhibitors: These drugs target the HER2 protein, blocking its activity and slowing or stopping cancer cell growth.

Clinical Trials: Participating in clinical trials for new options or combination solutions can be an option, especially for advanced or recurrent cancers.

2. Lower Urinary Tract Carcinoma
Surgery:

This includes tumor resection (surgical removal of the tumor) using traditional surgical methods or newly developed minimally invasive techniques.

The treatments for lower urinary tract carcinoma are similar to those described above, with some variations in surgical procedures, which are detailed below:

  • Transurethral Resection of Bladder Tumor (TURBT): This is the most common treatment for early-stage bladder cancer, usually performed for non-muscle-invasive cancers.
  • Cystectomy: Used for more advanced cancers, where part (partial cystectomy) or the entire bladder (radical cystectomy) may need to be removed.
  • Urethrectomy: If the cancer affects the urethra, part or all of the urethra may be removed, especially in advanced cases.

Immunohistochemistry (IHC) plays a crucial role in the diagnosis and management of urothelial cancer. It helps identify specific proteins and molecular markers in cancer cells, providing valuable insights into the tumor’s characteristics. By using IHC, doctors can differentiate urothelial cancer from other types of cancer, determine its aggressiveness, and choose the best options. This technique also aids in predicting responses to targeted options, allowing for more personalized and effective plans for patients. Some of the key biomarkers that can be identified using IHC in urothelial cancer include:

  • Human Epidermal Growth Factor Receptor 2 (HER2): A mutated protein involved in cell growth and division. It can be overexpressed in some urothelial cancers. Identifying HER2 helps doctors determine whether targeted options like HER2 inhibitors might be effective in treating the cancer.
  • Programmed Death Ligand 1 (PD-L1): A protein that cancer cells use to evade the immune system. In urothelial cancer, high levels of PD-L1 allow tumors to hide from the immune system. Identifying PD-L1 helps doctors determine whether immunotherapies like PD-1/PD-L1 inhibitors would be beneficial.
  • Ki-67: A protein found in growing and dividing cells. Higher levels of Ki-67 indicate rapid cell division, which is often seen in more aggressive tumors.

Clinical trials play a crucial role for several reasons:

Access to Innovative Options: Clinical trials offer individuals the opportunity to access novel possibilities, particularly crucial for serious conditions like urothelial cancer, where conventional options may be less effective.

Enhancing Outcomes: Participation in clinical trials allows patients to contribute valuable insights that may enhance survival rates and overall well-being for future urothelial cancer patients.

Hope for the Future: For many individuals dealing with urothelial cancer, involvement in a clinical trial instills hope, both for their own recovery and for the potential positive impact on future patients.

Comprehensive Medical Attention: Patients enrolled in clinical trials typically receive comprehensive care, with a dedicated team of healthcare providers and researchers closely monitoring their progress.

Promoting Research Advancements: Clinical trials play a pivotal role in advancing research, aiding scientists in understanding the effectiveness of new options and identifying which patients benefit the most. This can pave the way for the development of more effective approaches.

Next-Generation Sequencing (NGS) identifies genetic mutations in your cancer, known as biomarkers, that can match you with clinical trials offering targeted options. Some key biomarkers in urothelial carcinoma include:

FGFR3: Leads to uncontrolled cell growth, common in non-invasive cancers.

TP53: A tumor suppressor gene. Mutations in TP53 are associated with various cancers, including urothelial cancer, affecting tumor behavior and treatment response.

ERBB2: NGS can detect amplifications or mutations in the ERBB2 gene, which encodes the HER2 protein, guiding the use of HER2-targeted therapies.

PIK3CA: Mutations in the PIK3CA gene, which encodes a subunit of PI3K. It can affect responses to certain treatments, including hormone therapy and PI3K inhibitors.

CDKN2A: Mutations in CDKN2A disrupt cell cycle control, linked to more aggressive forms.

Knowing these biomarkers can help doctors recommend treatments tailored to your cancer and may improve your chances of joining clinical trials that offer the latest targeted options.

Cancer is an unfortunate reality that touches most of us at some point in our lives. If you or a loved one has cancer, you may have heard or read that clinical trials could offer access to innovative new options. But what exactly is a clinical trial? In this video, Massive Bio co-founder Arturo Loaiza-Bonilla, MD, explains how clinical trials work, what to expect if you enroll in one, and why a clinical trial can be an important option for many cancer patients.

We dream of the day when cancer disappears from our lives. Massive Bio is working tirelessly on achieving that goal.

The Latest in Urothelial Cancer Clinical Trial Options

Our matching system connects you with the most up-to-date clinical trials, opening new possibilities for those living with urothelial carcinoma. Through the MassiveBio platform, you can access detailed information about clinical trials for every stage of the disease. These trials include new options and combinations specifically designed to target urothelial carcinoma. By participating, you can actively fight the disease alongside our team.

How Our System Works

By analyzing your medical records and utilizing our advanced AI system, we identify clinical trials that may be a good fit for you. We also provide a personalized concierge service to ensure a smooth transition into these trials. Our dedicated team of nurses and doctors will guide you through every step, from beginning to end. These services are completely free for both you and your oncologist.

Understanding the Disease

What is Urothelial Cancer?

The most common type of cancer in the urothelial regions is urothelial carcinoma, also known as transitional cell carcinoma (TCC). It is the most common form of cancer in the lower urinary tract, affecting the bladder and urethra. It can also arise in the upper urinary tract, including the kidneys and ureters, though it is less common in these areas. This cancer starts in the urothelium, a special type of tissue that lines much of the urinary tract and serves as a barrier to hold urine while preventing toxins from re-entering the body. Urothelial cancers are often linked to genetic mutations, such as changes in the p53 gene, which can cause the urothelial cells to grow uncontrollably and invade nearby tissues. Risk factors like smoking, alcohol use, and chemical exposure also increase the likelihood of developing urothelial carcinoma.

Types of Urothelial Cancer

Urothelial cancer includes cancers that originate in the urothelial cells, which line much of the urinary tract. These cells are found in several parts of the body, leading to different types of urothelial cancer. The main areas affected by urothelial cancer include:

Bladder Urothelial Carcinoma: The most common type, originating in the bladder’s inner lining. It can be classified into two categories:

Non-muscle-invasive: Cancer confined to the bladder lining or just beneath it.

Muscle-invasive: Cancer that has spread into the bladder’s muscular wall.

Urethral Urothelial Carcinoma: This cancer develops in the urethra, the tube that carries urine from the bladder out of the body.

Upper Tract Urothelial Carcinoma: Occurring in the renal pelvis (the part of the kidney that collects urine before it moves to the ureter) or ureters (the tubes that carry urine from the kidneys to the bladder), these cancers are less common than bladder cancer.

Common Symptoms of Urothelial Cancer

Hematuria: Blood in the urine, causing it to appear pink, red, or brown.

Dysuria: Painful or burning sensations while urinating.

Pelvic or Lower Back Pain: Can develop as the cancer progresses and presses on nearby organs or nerves.

Urinary Urgency: A sudden, strong need to urinate, even when the bladder is not full.

Urinary Incontinence: Difficulty controlling urine flow.

Recognizing these symptoms early can make a crucial difference in your treatment options and outcomes. Don’t ignore symptoms like blood in your urine or pain during urination, as early detection often leads to more effective treatment.

Staging Urothelial Carcinoma

Understanding the stage of urothelial carcinoma is vital for determining how far the cancer has spread and what treatments are most appropriate. The stage helps doctors decide whether the tumor is limited to the bladder lining or has grown deeper into the muscle or other tissues. This information allows patients to feel informed and confident in their treatment choices.

1. Lower urinary tract urothelial carcinomas: This includes urothelial carcinomas that originate in the bladder and urethra. The stages are divided as follows:

  • Stage 0: The tumor affects only the inner lining of the bladder or urethra, without invading deeper layers.
  • Stage 1: An early stage where the cancer has invaded the lamina propria (a thin layer beneath the bladder or urethral lining) but has not yet reached the muscle layer.
  • Stage 2: A localized stage where the tumor has grown into the muscle layer, either the inner (superficial) or outer (deep) muscle.
  • Stage 3: A locally advanced stage where the tumor has spread into the surrounding fatty tissue or nearby organs (e.g., prostate, uterus, or vagina) or has spread to a single regional lymph node.
  • Stage 4: An advanced or metastatic stage where the tumor has spread to adjacent organs, multiple lymph nodes, or metastasized to distant organs.

2. Upper urinary tract urothelial carcinomas: This includes carcinomas that originate in the ureters or renal pelvis. The stages are divided as follows:

  • Stage 0: The cancer is limited to the inner lining of the ureter or renal pelvis and has not invaded deeper tissues.
  • Stage 1: An early stage where the cancer has grown from the inner lining into the layer just beneath it (lamina propria) but has not yet reached the muscle.
  • Stage 2: A localized stage where the tumor has spread into the muscle layer of the ureter or renal pelvis.
  • Stage 3: A locally advanced stage where the tumor has invaded the fat surrounding the ureter or renal pelvis.
  • Stage 4: An advanced stage where the cancer has spread to nearby lymph nodes, deeply invaded nearby organs (e.g., bladder, bowel, or abdominal wall), or metastasized to distant organs.

Treated vs. Untreated Urothelial Carcinoma

Treated Urothelial Carcinoma: Cancer that has undergone treatment, such as surgery, chemotherapy, immunotherapy, or radiation. Regular follow-ups are essential to monitor for recurrence.

Untreated Urothelial Carcinoma: Cancer that has been diagnosed but not yet treated. Clinical trials offer new treatment possibilities for both treated and untreated cases, providing access to cutting-edge therapies.

Resectable vs. Unresectable Urothelial Carcinoma

Resectable: Cancer that can be surgically removed. Tumors that have not spread too far can often be treated with surgery, offering a better chance of cure.

Unresectable: Cancer that cannot be completely removed by surgery due to its location or spread. Other treatments like chemotherapy, radiation, or targeted therapies are typically used in these cases.

Understanding whether your cancer is resectable or not is essential in choosing the best path and can open up options for advanced options in clinical trials.

Current Treatment Options

1. Upper Urinary Tract Carcinoma

Surgery:

The type of surgery you receive will mainly depend on the stage of your cancer, with emphasis on the size of the tumor.

I.Nephroureterectomy: This surgery is usually recommended for more advanced cancers or when the tumor has invaded deeper tissues. It is the most common treatment for urothelial carcinoma in the renal pelvis or ureter. The procedure involves removing the kidney, the affected ureter, and part of the bladder.

II.Segmental Ureterectomy: Recommended for smaller tumors confined to the ureter. It involves removing only the affected portion of the ureter.

III.Endoscopic Surgery: Minimally invasive procedures can be used for smaller, non-invasive tumors.

Intravesical Therapy: This treatment is typically recommended for early-stage cancers. It involves delivering medications (such as BCG or chemotherapy) directly into the renal pelvis to help prevent the cancer from returning or progressing.

Systemic Chemotherapy: Used for more advanced urothelial carcinoma that has spread beyond the kidney or ureter. This treatment involves administering anti-cancer drugs that circulate throughout the body to target cancer cells. It can also be used before or after surgery to reduce the risk of recurrence or to manage cancer that cannot be completely removed surgically.

Immunotherapy: This treatment helps the body’s immune system recognize and attack cancer cells. It is typically used for advanced, recurrent, or metastatic cancers, especially when other treatments have not been effective.

Anti-PDL1: These drugs block proteins that prevent immune cells from attacking tumors, thereby enhancing the immune response.

Radiation Therapy: In some cases, radiation can be used to treat urothelial carcinoma in the renal pelvis or ureter, particularly when surgery is not an option or to relieve symptoms in advanced cases.

Targeted Therapy: This type of treatment uses drugs designed to specifically target and block molecules or proteins that are essential for cancer cell growth and survival. Unlike traditional chemotherapy, targeted therapy focuses on attacking cancer cells while minimizing damage to healthy cells.

FGFR Inhibitors: These drugs block the abnormal activity of FGFR proteins, preventing cancer cells from multiplying and helping to shrink the tumor.

mTOR Inhibitors: These drugs block the activity of the mTOR protein, stopping the signals that encourage cancer cell growth and spread.

ERBB2 (HER2) Inhibitors: These drugs target the HER2 protein, blocking its activity and slowing or stopping cancer cell growth.

Clinical Trials: Participating in clinical trials for new options or combination therapies can be an option, especially for advanced or recurrent cancers.

2. Lower Urinary Tract Carcinoma

Surgery:

This includes tumor resection (surgical removal of the tumor) using traditional surgical methods or newly developed minimally invasive techniques.

The treatments for lower urinary tract carcinoma are similar to those described above, with some variations in surgical procedures, which are detailed below:

Transurethral Resection of Bladder Tumor (TURBT): This is the most common treatment for early-stage bladder cancer, usually performed for non-muscle-invasive cancers.

Cystectomy: Used for more advanced cancers, where part (partial cystectomy) or the entire bladder (radical cystectomy) may need to be removed.

Urethrectomy: If the cancer affects the urethra, part or all of the urethra may be removed, especially in advanced cases.

Immunohistochemistry (IHC) testing and Clinical Trials

Immunohistochemistry (IHC) plays a crucial role in the diagnosis and management of urothelial cancer. It helps identify specific proteins and molecular markers in cancer cells, providing valuable insights into the tumor’s characteristics. By using IHC, doctors can differentiate urothelial cancer from other types of cancer, determine its aggressiveness, and choose the best options. This technique also aids in predicting responses to targeted options, allowing for more personalized and effective plans for patients. Some of the key biomarkers that can be identified using IHC in urothelial cancer include:

Human Epidermal Growth Factor Receptor 2 (HER2): A mutated protein involved in cell growth and division. It can be overexpressed in some urothelial cancers. Identifying HER2 helps doctors determine whether targeted therapies like HER2 inhibitors might be effective.

Programmed Death Ligand 1 (PD-L1): A protein that cancer cells use to evade the immune system. In urothelial cancer, high levels of PD-L1 allow tumors to hide from the immune system. Identifying PD-L1 helps doctors determine whether immunotherapies like PD-1/PD-L1 inhibitors would be beneficial.

Ki-67: A protein found in growing and dividing cells. Higher levels of Ki-67 indicate rapid cell division, which is often seen in more aggressive tumors.

The Role of Clinical Trials in Urothelial Cancer

Clinical trials play a crucial role for several reasons:

Access to Innovative Options: Clinical trials offer individuals the opportunity to access novel possibilities, particularly crucial for serious conditions like urothelial cancer, where conventional options may be less effective.

Enhancing Outcomes: Participation in clinical trials allows patients to contribute valuable insights that may enhance survival rates and overall well-being for future urothelial cancer patients.

Hope for the Future: For many individuals dealing with urothelial cancer, involvement in a clinical trial instills hope, both for their own recovery and for the potential positive impact on future patients.

Comprehensive Medical Attention: Patients enrolled in clinical trials typically receive comprehensive care, with a dedicated team of healthcare providers and researchers closely monitoring their progress.

Promoting Research Advancements: Clinical trials play a pivotal role in advancing research, aiding scientists in understanding the effectiveness of new options and identifying which patients benefit the most. This can pave the way for the development of more effective therapeutic approaches.

NGS Testing and Clinical Trials

Next-Generation Sequencing (NGS) identifies genetic mutations in your cancer, known as biomarkers, that can match you with clinical trials offering targeted options. Some key biomarkers in urothelial carcinoma include:

FGFR3: Leads to uncontrolled cell growth, common in non-invasive cancers.

TP53: A tumor suppressor gene. Mutations in TP53 are associated with various cancers, including urothelial cancer, affecting tumor behavior and treatment response.

ERBB2: NGS can detect amplifications or mutations in the ERBB2 gene, which encodes the HER2 protein, guiding the use of HER2-targeted therapies.

PIK3CA: Mutations in the PIK3CA gene, which encodes a subunit of PI3K. It can affect responses to certain treatments, including hormone therapy and PI3K inhibitors.

CDKN2A: Mutations in CDKN2A disrupt cell cycle control, linked to more aggressive forms.

Knowing these biomarkers can help doctors recommend options tailored to your cancer and may improve your chances of joining clinical trials that offer the latest targeted options.

Dr. Arturo explains:

What Are Clinical Trials?

Cancer is an unfortunate reality that touches most of us at some point in our lives. If you or a loved one has cancer, you may have heard or read that clinical trials could offer access to innovative new options. But what exactly is a clinical trial? In this video, Massive Bio co-founder Arturo Loaiza-Bonilla, MD, explains how clinical trials work, what to expect if you enroll in one, and why a clinical trial can be an important option for many cancer patients.

We dream of the day when cancer disappears from our lives. Massive Bio is working tirelessly on achieving that goal.

How Massive Bio Helps Patients With Urothelial Cancer
1
Consent Signed

Fill out our contact form and sign our consent form

2
Data Collection

We collect your medical records securely

3
Pre Screening

Our expert nurses check clinical trials and contact you

4
Concierge Services

We support you with appointments, travel, and accommodation

Let’s explore your options and bring new hope to your journey.

We offer a quick, easy and FREE way to find urothelial cancer clinical research opportunities for patients like you. With our unique clinical trial matching system (CTMS) and team specialized in oncology, we can rapidly match you to a clinical research study for those diagnosed with urothelial cancer.

[EN] Ads Landing Pages - United States & Canada - English
Let's Explore Your Options
By filling out this form, you're consenting only to release your medical records. You're not agreeing to participate in clinical trials yet.
Frequently asked questions

To enroll in clinical trial, you must meet highly specific criteria that’s established by the researchers who are conducting the investigation. That includes detailed information about type of cancer, treatment history, response to treatment, and other data that is collected in medical records.

If you are being treated for cancer or any other disease, your doctor should have a complete record of your medical care, including specific information about what form of the disease you have and what treatments you have received. Your patient relations coordinator will contact you and inform you about the details.

Massive Bio provides its services to the patients and their doctors at no cost—you won’t have to pay anything to receive a clinical-research matching report. There are no hidden costs involved.

Massive Bio strictly adheres to all HIPAA guidelines and international regulations focused on maintaining your privacy. We take extra measures to secure your personal information, ensuring it is protected beyond the mandatory requirements.

Your doctor may know of a clinical research study being conducted in your area that’s recruiting participants and is right for you. However, Massive Bio uses its artificial intelligence powered platform to match patients to clinical research studies that give you the best chance of a positive outcome and are being conducted in a geographical location that makes sense for you.

Yes, Massive Bio keeps your doctor up to date on your status throughout your participation.